Ryde, S. J. S., Bowen-Simpkins, K., Bowen-Simpkins, P., Evans, W. D.  ORCID: https://orcid.org/0000-0003-0013-8205, Morgan, W. D. and Compston, J. E.
      1994.
      
      The effect of oestradiol implants on regional and total bone mass: a three year longitudinal study.
      Clinical Endocrinology
      40
      
        (1)
      
      , pp. 33-38.
      
      10.1111/j.1365-2265.1994.tb02440.x
    
  
  
       
       
     
         | 
      
Abstract
Objective: Although there is evidence from cross-sectional studies that percutaneous oestrogen administration protects against menopausal bone loss, few longitudinal data are available. We have examined the effect of 3 years' treatment with percutaneous oestradiol on total body calcium, spinal trabecular bone mineral density and radial bone mineral content in post-menopausal women. Design and patients: Twenty-nine post-menopausal women, aged 37–55 years, who had undergone hysterectomy and had experienced the onset of menopausal symptoms within the previous 2 years, were studied before and for 3 years during hormone replacement with oestradiol implants, given at approximately 6-monthly intervals. Measurements: Total body calcium was measured by prompt gamma neutron activation analysis, spinal trabecular bone mineral density by quantitative computed tomography and radial bone mineral content by single-photon absorptiometry. Results: There was a significant increase in the mean total body calcium, spinal trabecular bone mineral density and radial bone mineral content over the 3 years of the study. The mean (± SEM) percentage change per annum was +2 4% (±0.8) for total body calcium (P <0 01), + 3.3% (±0.6) for spinal trabecular bone mineral density (P < 0.001) and +12% (± 0.6) for radial bone mineral content (P < 0 05). Conclusions: Percutaneous oestradiol replacement therapy prevents menopausal bone loss and is associated with a sustained and significant increase in total body calcium, spinal trabecular bone mineral density and radial bone mineral content over a 3-year treatment period. Oestradiol implants thus have skeletal effects comparable to those of oral or transdermal oestrogens.
| Item Type: | Article | 
|---|---|
| Date Type: | Publication | 
| Status: | Published | 
| Schools: | Schools > Medicine | 
| Publisher: | Society for Endocrinology | 
| ISSN: | 0300-0664 | 
| Date of Acceptance: | 8 June 1993 | 
| Last Modified: | 10 Nov 2022 10:03 | 
| URI: | https://orca.cardiff.ac.uk/id/eprint/145528 | 
Citation Data
Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
![]()  | 
              Edit Item | 

							



 Dimensions
 Dimensions